These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23512153)

  • 21. [Foam sclerotherapy].
    Partsch B
    Ther Umsch; 2011 Mar; 68(3):159-62. PubMed ID: 21360462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Foam sclerotherapy for spouting haemorrhage in patients with varicose veins.
    Hamahata A; Yamaki T; Osada A; Fujisawa D; Sakurai H
    Eur J Vasc Endovasc Surg; 2011 Jun; 41(6):856-8. PubMed ID: 21420881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial.
    Ukritmanoroat T
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S35-40. PubMed ID: 21717876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polidocanol for endovenous microfoam sclerosant therapy.
    Eckmann DM
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1919-27. PubMed ID: 19912070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of side effects using carbon dioxide-oxygen foam for chemical ablation of superficial veins of the lower extremity.
    Morrison N; Neuhardt DL; Rogers CR; McEown J; Morrison T; Johnson E; Salles-Cunha SX
    Eur J Vasc Endovasc Surg; 2010 Sep; 40(3):407-13. PubMed ID: 20547080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should foam made with physiologic gases be the standard in sclerotherapy?
    Wong M
    Phlebology; 2015 Oct; 30(9):580-6. PubMed ID: 25392457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications.
    Frullini A; Cavezzi A
    Dermatol Surg; 2002 Jan; 28(1):11-5. PubMed ID: 11991262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
    Rabe E; Otto J; Schliephake D; Pannier F
    Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new method for using radiopaque sclerosing foam to treat venous malformations.
    Li K; Liu YR; Chen AW; Liu SH
    Dermatol Surg; 2015 Jun; 41(6):726-30. PubMed ID: 25973562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Foam and liquid sclerotherapy for varicose veins.
    Coleridge Smith P
    Phlebology; 2009; 24 Suppl 1():62-72. PubMed ID: 19307442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection.
    Cavezzi A; Tessari L
    Phlebology; 2009 Dec; 24(6):247-51. PubMed ID: 19952380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basic physiochemical and rheological properties of detergent sclerosants.
    Wong K; Chen T; Connor DE; Behnia M; Parsi K
    Phlebology; 2015 Jun; 30(5):339-49. PubMed ID: 24671525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid and Foam Sclerotherapy for Spider and Varicose Veins.
    Gibson K; Gunderson K
    Surg Clin North Am; 2018 Apr; 98(2):415-429. PubMed ID: 29502781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiochemical properties and reproducibility of air-based sodium tetradecyl sulphate foam using the Tessari method.
    Watkins MR; Oliver RJ
    Phlebology; 2017 Jul; 32(6):390-396. PubMed ID: 27329670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Investigation on the Influence of Hyaluronic Acid on Polidocanol Foam Stability.
    Chen AW; Liu YR; Li K; Liu SH
    Dermatol Surg; 2016 Jan; 42(1):56-8. PubMed ID: 26671207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saphenous ablation: sclerosant or sclerofoam?
    Coleridge Smith P
    Semin Vasc Surg; 2005 Mar; 18(1):19-24. PubMed ID: 15791549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and ex vivo evaluation of the biological performance of sclerosing foams.
    Bottaro E; Paterson JAJ; Quercia L; Zhang X; Hill M; Patel VA; Jones SA; Lewis AL; Millar TM; Carugo D
    Sci Rep; 2019 Jul; 9(1):9880. PubMed ID: 31285447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blocking the saphenofemoral junction during ultrasound-guided foam sclerotherapy-- assessment of a presumed safety-measure procedure.
    Ceulen RP; Jagtman EA; Sommer A; Teule GJ; Schurink GW; Kemerink GJ
    Eur J Vasc Endovasc Surg; 2010 Dec; 40(6):772-6. PubMed ID: 20926321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial.
    Alòs J; Carreño P; López JA; Estadella B; Serra-Prat M; Marinel-Lo J
    Eur J Vasc Endovasc Surg; 2006 Jan; 31(1):101-7. PubMed ID: 16226901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleomycin Polidocanol Foam (BPF) Stability - In Vitro Evidence for the Effectiveness of a Novel Sclerosant for Venous Malformations.
    Sun Y; Gu H; Yang X; Cai R; Shang Y; Hu L; Wang Y; Chen H; Lin X
    Eur J Vasc Endovasc Surg; 2020 Jun; 59(6):1011-1018. PubMed ID: 32063463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.